Literature DB >> 22689911

MpzR98C arrests Schwann cell development in a mouse model of early-onset Charcot-Marie-Tooth disease type 1B.

Mario A C Saporta1, Brian R Shy, Agnes Patzko, Yunhong Bai, Maria Pennuto, Cinzia Ferri, Elisa Tinelli, Paola Saveri, Dan Kirschner, Michelle Crowther, Cherie Southwood, Xingyao Wu, Alexander Gow, M Laura Feltri, Lawrence Wrabetz, Michael E Shy.   

Abstract

Mutations in myelin protein zero (MPZ) cause Charcot-Marie-Tooth disease type 1B. Many dominant MPZ mutations, including R98C, present as infantile onset dysmyelinating neuropathies. We have generated an R98C 'knock-in' mouse model of Charcot-Marie-Tooth type 1B, where a mutation encoding R98C was targeted to the mouse Mpz gene. Both heterozygous (R98C/+) and homozygous (R98C/R98C) mice develop weakness, abnormal nerve conduction velocities and morphologically abnormal myelin; R98C/R98C mice are more severely affected. MpzR98C is retained in the endoplasmic reticulum of Schwann cells and provokes a transitory, canonical unfolded protein response. Ablation of Chop, a mediator of the protein kinase RNA-like endoplasmic reticulum kinase unfolded protein response pathway restores compound muscle action potential amplitudes of R98C/+ mice but does not alter the reduced conduction velocities, reduced axonal diameters or clinical behaviour of these animals. R98C/R98C Schwann cells are developmentally arrested in the promyelinating stage, whereas development is delayed in R98C/+ mice. The proportion of cells expressing c-Jun, an inhibitor of myelination, is elevated in mutant nerves, whereas the proportion of cells expressing the promyelinating transcription factor Krox-20 is decreased, particularly in R98C/R98C mice. Our results provide a potential link between the accumulation of MpzR98C in the endoplasmic reticulum and a developmental delay in myelination. These mice provide a model by which we can begin to understand the early onset dysmyelination seen in patients with R98C and similar mutations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689911      PMCID: PMC3381724          DOI: 10.1093/brain/aws140

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  42 in total

1.  Cytoplasmic IRE1alpha-mediated XBP1 mRNA splicing in the absence of nuclear processing and endoplasmic reticulum stress.

Authors:  Sung Hoon Back; Kyungho Lee; Elizabeth Vink; Randal J Kaufman
Journal:  J Biol Chem       Date:  2006-04-27       Impact factor: 5.157

2.  Effect of an R69C mutation in the myelin protein zero gene on myelination and ion channel subtypes.

Authors:  Yunhong Bai; Emilia Ianokova; Qin Pu; Khaled Ghandour; Rock Levinson; Jean-Jacques Martin; Chantal Ceuterick-de Groote; Radim Mazanec; Pavel Seeman; Michael E Shy; Jun Li
Journal:  Arch Neurol       Date:  2006-12

3.  Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants.

Authors:  Mehrdad Khajavi; Ken Inoue; Wojciech Wiszniewski; Tomoko Ohyama; G Jackson Snipes; James R Lupski
Journal:  Am J Hum Genet       Date:  2005-09-30       Impact factor: 11.025

Review 4.  De novo mutation (Arg98-->Cys) of the myelin P0 gene and uncompaction of the major dense line of the myelin sheath in a severe variant of Charcot-Marie-Tooth disease type 1B.

Authors:  A Komiyama; A Ohnishi; K Izawa; S Yamamori; H Ohashi; O Hasegawa
Journal:  J Neurol Sci       Date:  1997-07       Impact factor: 3.181

5.  CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum.

Authors:  H Zinszner; M Kuroda; X Wang; N Batchvarova; R T Lightfoot; H Remotti; J L Stevens; D Ron
Journal:  Genes Dev       Date:  1998-04-01       Impact factor: 11.361

6.  Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination.

Authors:  L E Warner; M J Hilz; S H Appel; J M Killian; E H Kolodry; G Karpati; S Carpenter; G V Watters; C Wheeler; D Witt; A Bodell; E Nelis; C Van Broeckhoven; J R Lupski
Journal:  Neuron       Date:  1996-09       Impact factor: 17.173

7.  ASK1 is essential for JNK/SAPK activation by TRAF2.

Authors:  H Nishitoh; M Saitoh; Y Mochida; K Takeda; H Nakano; M Rothe; K Miyazono; H Ichijo
Journal:  Mol Cell       Date:  1998-09       Impact factor: 17.970

8.  Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice.

Authors:  Maria Pennuto; Elisa Tinelli; Mariachiara Malaguti; Ubaldo Del Carro; Maurizio D'Antonio; David Ron; Angelo Quattrini; M Laura Feltri; Lawrence Wrabetz
Journal:  Neuron       Date:  2008-02-07       Impact factor: 17.173

9.  Structure and stability of internodal myelin in mouse models of hereditary neuropathy.

Authors:  Robin L Avila; Hideyo Inouye; Rena C Baek; Xinghua Yin; Bruce D Trapp; M Laura Feltri; Lawrence Wrabetz; Daniel A Kirschner
Journal:  J Neuropathol Exp Neurol       Date:  2005-11       Impact factor: 3.685

10.  Different intracellular pathomechanisms produce diverse Myelin Protein Zero neuropathies in transgenic mice.

Authors:  Lawrence Wrabetz; Maurizio D'Antonio; Maria Pennuto; Gabriele Dati; Elisa Tinelli; Pietro Fratta; Stefano Previtali; Daniele Imperiale; Jurgen Zielasek; Klaus Toyka; Robin L Avila; Daniel A Kirschner; Albee Messing; M Laura Feltri; Angelo Quattrini
Journal:  J Neurosci       Date:  2006-02-22       Impact factor: 6.167

View more
  30 in total

Review 1.  Endoplasmic reticulum stress and the unfolded protein response in disorders of myelinating glia.

Authors:  Benjamin L L Clayton; Brian Popko
Journal:  Brain Res       Date:  2016-04-04       Impact factor: 3.252

2.  Phenotypic presentation of the Ser63Del MPZ mutation.

Authors:  Lindsey J Miller; Agnes Patzko; Richard A Lewis; Michael E Shy
Journal:  J Peripher Nerv Syst       Date:  2012-06       Impact factor: 3.494

3.  Gene therapy, CMT1X, and the inherited neuropathies.

Authors:  Michael E Shy
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-14       Impact factor: 11.205

4.  Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice.

Authors:  Agnes Patzkó; Yunhong Bai; Mario A Saporta; István Katona; Xingyao Wu; Domenica Vizzuso; M Laura Feltri; Suola Wang; Lisa M Dillon; John Kamholz; Daniel Kirschner; Fazlul H Sarkar; Lawrence Wrabetz; Michael E Shy
Journal:  Brain       Date:  2012-12       Impact factor: 13.501

5.  Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.

Authors:  Justin T Marinko; Hui Huang; Wesley D Penn; John A Capra; Jonathan P Schlebach; Charles R Sanders
Journal:  Chem Rev       Date:  2019-01-04       Impact factor: 60.622

6.  Overexpression of CHOP in Myelinating Cells Does Not Confer a Significant Phenotype under Normal or Metabolic Stress Conditions.

Authors:  Cherie M Southwood; Bozena Fykkolodziej; Kathleen J Maheras; Danielle M Garshott; Molly Estill; Andrew M Fribley; Alexander Gow
Journal:  J Neurosci       Date:  2016-06-22       Impact factor: 6.167

7.  Sustained Expression of Negative Regulators of Myelination Protects Schwann Cells from Dysmyelination in a Charcot-Marie-Tooth 1B Mouse Model.

Authors:  Francesca Florio; Cinzia Ferri; Cristina Scapin; M Laura Feltri; Lawrence Wrabetz; Maurizio D'Antonio
Journal:  J Neurosci       Date:  2018-04-02       Impact factor: 6.167

Review 8.  Inherited peripheral neuropathies.

Authors:  Mario A Saporta; Michael E Shy
Journal:  Neurol Clin       Date:  2013-03-05       Impact factor: 3.806

9.  Curcumin facilitates a transitory cellular stress response in Trembler-J mice.

Authors:  Yuji Okamoto; Davut Pehlivan; Wojciech Wiszniewski; Christine R Beck; G Jackson Snipes; James R Lupski; Mehrdad Khajavi
Journal:  Hum Mol Genet       Date:  2013-07-11       Impact factor: 6.150

10.  Sox2 expression in Schwann cells inhibits myelination in vivo and induces influx of macrophages to the nerve.

Authors:  Sheridan L Roberts; Xin-Peng Dun; Robin D S Doddrell; Thomas Mindos; Louisa K Drake; Mark W Onaitis; Francesca Florio; Angelo Quattrini; Alison C Lloyd; Maurizio D'Antonio; David B Parkinson
Journal:  Development       Date:  2017-07-25       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.